The vote along party lines was 230-192.
Speaker Nancy Pelosi’s bill would cap Medicare recipients’ out-of-pocket costs for medicines at $2,000 a year. It would use about $360 billion of its projected 10-year savings from lower drug costs to establish Medicare coverage for dental care, hearing and vision, filling major gaps for seniors.
But the legislation has no chance of passing the Republican-controlled Senate, and the White House has issued a veto threat. Still, Democrats saw a victory in the message their bill sends to voters.
“I think that it is going to be too hot to handle for the Republicans,” said Pelosi, D-Calif.
She is claiming bragging rights because her bill would deliver on the promise that Donald Trump made as a candidate in 2016, when he said he would “negotiate like crazy” to lower prescription drug prices for Medicare recipients. It’s a pledge that Trump has backed away from as president.
The bill is named for the late Rep. Elijah Cummings, the Baltimore Democrat who fought during his congressional career to lower prescription drug costs.
In a speech on the House floor on Thursday, House Speaker Nancy Pelosi touched her hand to her heart as she said the legislation is “named for our great and departed, may he rest in peace, Elijah Cummings."
In 2018, Cummings accused President Donald Trump of abandoning a campaign proposal to allow Medicare to directly negotiate lower prices with drug companies.
That was the aim of the legislation in Cummings’ name – to empower the federal government to compel lower prices.
“While we deeply miss Elijah, we can continue to keep his memory alive by advancing legislation like H.R. 3 and by working every single day to make life better for our fellow Americans,” said U.S. Rep. John Sarbanes, a Baltimore County Democrat.
The Trump administration said it favors drug-cost relief, but that the Democrats’ bill would hamper drug companies from bringing “innovative therapeutics” to market, ultimately harming patients.
Cummings, who had cancer, died on Oct. 17
For months, Pelosi’s office and the White House had talked privately about Medicare negotiations. But the sides went their own ways partly because administration officials concluded her approach could never win support among congressional Republicans.
Trump now favors a bipartisan compromise in the Senate that would limit drug price increases and cap what seniors pay out-of-pocket, but would not authorize Medicare negotiations.
Negotiations are “the heart of the matter,” Pelosi insisted.
High prescription drug prices consistently register as the public’s top health care concern. But it’s unclear in a capital divided over Trump’s impeachment that any major legislation will pass before next year’s elections.
Pelosi’s bill “is a serious proposal, but everyone knows that the Senate isn’t going to go for it,” said John Rother, CEO of the National Coalition on Health.
“It is about legislating, but even more it’s about establishing a platform that Democrats can run on going into the next election cycle and lays the groundwork for legislative activity in 2021,” Rother said. His organization is an umbrella group that represents health care industry groups and consumers.
The pharmaceutical industry is strongly opposed to the bill. Among the groups backing it is AARP.
Medicare’s popular prescription drug benefit is delivered through private insurers. Republicans say the government has no business setting prices for medicines. They argue that the hit on the pharmaceutical industry’s bottom line will stifle innovation, discouraging investment in the hunt for cures for Alzheimer’s and other intractable illnesses.
House Republican leader Kevin McCarthy of California accused Democrats of putting politics over solutions, “catering to their progressive base by opening the door to a government takeover of our prescription drug market.”
Republicans point to a major concern about the legislation: that it would result in fewer drugs coming to market. But there’s debate about the extent of the expected impact.
The nonpartisan Congressional Budget Office estimates about 3% to 10% fewer new drugs. The White House Council of Economic Advisers says it could be much higher, up to one-third of new medications.
The Senate bill the White House is backing steers clear of negotiations. It would cap seniors’ out-of-pocket costs, at $3,100 a year, and require drugmakers to pay Medicare rebates if companies raise prices above inflation. Majority Leader Mitch McConnell hasn’t said if or when he’ll bring it to the floor.
PREVIOUS ARTICLE
